Novogen Enrolls First Ovarian Cancer Patient in Cantrixil Phase 1 Trial

Novogen Enrolls First Ovarian Cancer Patient in Cantrixil Phase 1 Trial
Novogen enrolled the first patient into a Phase 1 clinical trial evaluating its lead candidate Cantrixil (TRX-E-002-1) in ovarian cancer patients. “The commencement of this trial represents a further step in Novogen’s transition to a clinical stage development company, and we are excited to be working with leading clinicians in the U.S. and Australia on

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *